CDER Established Quantitative Medicine Center of Excellence

The Center for Drug Evaluation and Research launched a new body to coordinate its quantitative medicine efforts.

Updated on Oct. 5, 2026 in Mathematics

Isometric editorial illustration of a metallic molecular model composed of spheres and rods on a platform, representing scientific regulatory precision. — The Center for Drug Evaluation and Research has launched the Quantitative Medicine Center of Excellence to coordinate drug development policy and scientific efforts across its offices. AI Illustration. Upload story photo >

Live Poll

Should government drug regulators centralize their scientific coordination to improve how new medicines are developed?

The Center for Drug Evaluation and Research has established the Quantitative Medicine Center of Excellence. This new body serves to coordinate quantitative medicine practices across the CDER organization.

Why it matters

The center aims to maximize synergies between CDER offices to strengthen outreach, education, and policy development. By centralizing these efforts, it seeks to facilitate the consistent application of quantitative medicine for drug development.

The center focuses on three distinct operational areas: Applied Regulatory Science, Enterprise Planning and Coordination, and Education and Ecosystem Development. These pillars guide the integration of quantitative medicine across the FDA drug review process.

The players

Center for Drug Evaluation and Research

This is a branch of the U.S. Food and Drug Administration that evaluates new drugs before they can be sold in the United States.

The details

The center functions as a cooperative, coordinating body that leverages strategic planning to harmonize efforts across the entire CDER enterprise. It works to streamline collaboration on education and policy while maintaining a focus on scientific regulatory application.

The center published its Progress and Priorities Report in 2025.

The Big Picture

The center follows a pattern set by the FDA's Critical Path Initiative by formalizing internal collaboration to improve the efficiency of drug development. This shift marks an evolution toward standardized, institution-wide quantitative frameworks rather than siloed regulatory review.

This development could eventually lead to more efficient drug approval timelines and more consistent safety data reporting. Patients may benefit from a more rigorous application of quantitative medicine in the development of new pharmaceutical products.

The takeaway

Centralizing quantitative medicine efforts is part of a larger push to modernize how complex drug data is analyzed across government agencies. Experts suggest this cooperative approach will help keep regulatory science aligned with rapid advancements in pharmaceutical research.